A mini-review on the current COVID-19 therapeutic strategies

Document Type : Review Article


Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran


The coronavirus outbreak (COVID-19) started in china, on 31 December 2019. COVID-19 is a severe acute respiratory syndrome. Research on COVID-19 treatment strategies for development of an effective drug therapy has attracted worldwide attention recently. So far, no certain cure or specific vaccine has been suggested by Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) to fight this deadly disease. However, several different treatment protocols have been proposed based on older drugs. Researchers around the world still attempt to evaluate them in clinical trials. In this mini review, we summarize the available drugs that have been used in the treatment of COVID-19 based on the existing guidelines.

Graphical Abstract

A mini-review on the current COVID-19 therapeutic strategies


1] Z. Anna L, and Z. Robert M, Fractal kinetics of COVID-19 pandemic. medRxiv (2020).
[2] R. Qiurong, et al., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive. Care. Med., 46 (2020) 846-848.
3] Organization, W.H., Coronavirus disease 2019 (‎ COVID-19)‎: situation report 51(2020).
[4] C. Marco, et al., Features, Evaluation and Treatment Coronavirus (COVID-19), in StatPearls [Internet]. (2020) StatPearls Publishing.
[5] L. Xiaowei, et al., Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal., 10 (2020) 102-108.
[6] S. Catrin, et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int. J. Surg., 76 (2020) 71-76.
[7] A Hussin, R. and B. Siddappa N, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun., 109 (2020) 102433.
[8] Y. Yongshi, et al., The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun., 109 (2020) 102434.
[9] P. Noah C, et al., The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol., 49 (2020) 717-726.
[10] Z. Lei, and L. Yunhui, Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol., 92 (2020) 479-490.
[11] D. R. Carlos, and M. Preeti N, COVID-19—new insights on a rapidly changing epidemic. Jama., 323 (2020) 1341-1343.
[12] Z. Yadi, , et al., Network -based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell. Discov., 6 (2020) 1-18.
[13] W. Junmei, Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) Through Computational Drug Repurposing Study (2020).
[14] J. Zhenming, et al., Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. Nature., (2020) DOI: 10.1101/2020.02.26.964882.
[15] A. E. Abdo, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life. Sci., 248 (2020) 117477.
[16] S. Micholas, and S. Jeremy C, Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface., (2020) DOI: 10.26434/chemrxiv.11871402.v4.
[17] F. Ayman, et al., Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning. ChemRxiv., (2020) DOI: 10.26434/chemrxiv.12049647.v1.
[18] G. Yiyue, et al., A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. BioRxiv., (2020) DOI: 10.1101/2020.03.11.986836.
[19] S. Balamurugan, et al., Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian. Pac. J. Allergy. Immunol., 38 (2020) 10-18.
[20] W. Manli, et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell. Res., 30 (2020) 269-271.
[21] G. Philippe, et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents., 56 (2020)105949.
[22] V. Thirumalaisamy P, and M. Christian G, The COVID-19 epidemic. Trop. Med. Int. Health., 25 (2020) 278-280.
[23] S. Tanu, A Review of Coronavirus Disease-2019 (COVID-19). Indian. J. Pediatr., 87 (2020) 281-286
[24] C. Wei, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open. Forum. Infect. Dis., 7 (2020) ofaa102.
[25] K. Kai, and C. Jon, Race to find COVID-19 treatments accelerates. Sci., 367 (2020) 1412-1413.
[26] T. Janice Hopkins, Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. B. M. J., 368) 2020 .( m1256
[27] D. Liying, H. Shasha, and G. Jianjun, Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug. Discov. Ther., 14 (2020) 58-60.
[28] A. MHB, Need to test Azithromycin as first-line therapy for Covid-19.
[29] L. Caly, et al., The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res., 178 (2020) 104787.